A consolidated subsidiary of Mitsubishi Tanabe Pharma，P.T. Tanabe Indonesia，started marketing Livalo (pitavastatin)，a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor)，in Indonesia on May 1，2012.
The launch comes after P.T. Tanabe Indonesia received regulatory approval in November 2011.